Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

INDIANAPOLIS (AP) — INDIANAPOLIS (AP) — Eli Lilly and Co. (LLY) on Thursday reported first-quarter profit of $2.76 billion. The Indianapolis-based company said it had net income of $3.06 per share.

Short interest in Eli Lilly and Co (NYSE:LLY) decreased during the last reporting period, falling from 7.02M to 6.43M. This put 0.81% of the company's publicly available shares short. Short ...

The inspiring story of Lilly Ledbetter, a former tire plant supervisor from Gadsden who became a national symbol for equal ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...

The strategy comes as rival Eli Lilly & Co. is working with telehealth firms to distribute lower-cost vials of its own ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Critics of the NRC say its red tape and lengthy authorization timelines stifle innovation, but handing some of its ...

Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer ...

Meanwhile, Novo Nordisk struck deals with several telehealth companies to sell its GLP-1 drug semaglutide for obesity ...